Flow-cytometry phenotypic assessment of immune cell subsets reflecting function for the identification of breast cancer patients receiving vaccine plus docetaxel with longer progression-free survival

Italia Grenga; Renee N Donahue; James L Gulley; Christopher Heery; Ravi A Madan; Jeffrey Schlom; Benedetto Farsaci

首页> 外文期刊>Journal for ImmunoTherapy of Cancer >Flow-cytometry phenotypic assessment of immune cell subsets reflecting function for the identification of breast cancer patients receiving vaccine plus docetaxel with longer progression-free survival

【24h】

Flow-cytometry phenotypic assessment of immune cell subsets reflecting function for the identification of breast cancer patients receiving vaccine plus docetaxel with longer progression-free survival

机译：免疫细胞亚群的流式细胞表型评估反映功能，用于识别接受疫苗加多西他赛的乳腺癌患者，其无进展生存期更长

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal for ImmunoTherapy of Cancer》 |2013年第s1期|共页
作者
Italia Grenga; Renee N Donahue; James L Gulley; Christopher Heery; Ravi A Madan; Jeffrey Schlom; Benedetto Farsaci;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor [J] . Inomata Minehiko, Kado Tomonobu, Okazawa Seisuke, Anticancer Research: International Journal of Cancer Research and Treatment . 2019,第12期

机译：外周PD1阳性CD4 T淋巴细胞计数可以预测非小细胞肺癌接受免疫检查点抑制剂的患者的无进展生存期
2. Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy. [J] . Lipton A, Leitzel K, Ali SM, Cancer: A Journal of the American Cancer Society . 2011,第21期

机译：人表皮生长因子受体2（HER2）胞外域水平与接受拉帕替尼单药治疗的HER2阳性转移性乳腺癌患者的无进展生存相关。
3. Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy [J] . Allan Lipton MD, Kim Leitzel MSc, Suhail M. Ali MD, Cancer . 2011,第21期

机译：人表皮生长因子受体2（HER2）细胞外结构域水平与接受拉帕替尼单药治疗的HER2阳性转移性乳腺癌患者的无进展生存相关
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. Toll-like receptor (TLR) expression and function of immune system cells from metastatic breast cancer patients with circulating tumor cells. [D] . Green, Taryn Lindsey. 2013

机译：Toll样受体（TLR）的表达和具有循环肿瘤细胞的转移性乳腺癌患者免疫系统细胞的功能。
6. Flow-cytometry phenotypic assessment of immune cell subsets reflecting function for the identification of breast cancer patients receiving vaccine plus docetaxel with longer progression-free survival [O] . Italia Grenga, Renee N Donahue, James L Gulley, 2013

机译：免疫细胞亚群的流式细胞表型评估反映功能用于识别接受疫苗加多西他赛治疗的乳腺癌患者其无进展生存期更长
7. Flow-cytometry phenotypic assessment of immune cell subsets reflecting function for the identification of breast cancer patients receiving vaccine plus docetaxel with longer progression-free survival [O] . Italia Grenga, Renee N Donahue, James L Gulley, 2013

机译：免疫细胞亚群的流式细胞表型评估反映功能，用于识别接受疫苗加多西他赛治疗的乳腺癌患者，其无进展生存期更长

Flow-cytometry phenotypic assessment of immune cell subsets reflecting function for the identification of breast cancer patients receiving vaccine plus docetaxel with longer progression-free survival

著录项

相似文献

相关主题

期刊订阅